PureTech's Seaport Publishes New Glyph Platform Data
Why we think this is good
The RNS highlights positive developments with PureTech's Glyph platform, which has demonstrated increased lymphatic transport and drug absorption for an immunomodulatory drug. The research expands the understanding of lymphatic delivery and offers insights for more effectively designing drugs with higher exposures at their intended targets. The Glyph platform has been clinically validated and is being applied across Seaport's pipeline of novel neuropsychiatric medicines, with potential for broader applications beyond CNS and neuropsychiatry. No clear negative factors were identified in the RNS.
Key Points
- New data published showcasing Glyph platform's ability to enhance drug transport through the lymphatic system
- Up to 55% lymphatic transport and two-fold higher release in lymph nodes compared to previous linkers
- Research expands understanding of lymphatic delivery and offers insights for designing more effective drugs
- Glyph platform clinically validated and being applied across Seaport's pipeline of neuropsychiatric medicines
- Potential for broader applications of Glyph platform beyond CNS and neuropsychiatry
Summary
PureTech Health's founded entity, Seaport Therapeutics, has published new data demonstrating the Glyph platform's ability to enhance drug transport through the lymphatic system. The research shows the Glyph platform can increase lymphatic transport and drug absorption, with up to 55% lymphatic transport and two-fold higher release in lymph nodes compared to previous linkers. This expands the understanding of lymphatic delivery and offers insights for designing more effective drugs. The Glyph platform has been clinically validated and is being applied across Seaport's pipeline of neuropsychiatric medicines, with potential for broader applications beyond CNS and neuropsychiatry.